Related Experiment Video
Updated: Mar 23, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
The Roles of MDM2 and MDMX in Cancer
Orit Karni-Schmidt1, Maria Lokshin1, Carol Prives1
1Department of Biological Sciences, Columbia University, New York, NY 10027;
Abstract:
For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been shown to exert oncogenic activity. These two proteins are best understood as negative regulators of the p53 tumor suppressor, although they may have additional p53-independent roles. Understanding the dysregulation of MDM2 and MDMX in human cancers and how they function either together or separately in tumorigenesis may improve methods of diagnosis and for assessing prognosis. Targeting the proteins themselves, or their regulators, may be a promising therapeutic approach to treating some forms of cancer.
Insights
MDM2 and MDMX proteins promote cancer by inhibiting the p53 tumor suppressor. Understanding their roles in cancer may lead to new diagnostic and therapeutic strategies targeting these oncogenic proteins.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MDM2 and MDMX (MDM4) are oncogenic proteins with over 25 years of research.
- They primarily function as negative regulators of the p53 tumor suppressor protein.
- Potential p53-independent roles in tumorigenesis are also being investigated.
Purpose of the Study:
- To explore the dysregulation of MDM2 and MDMX in human cancers.
- To elucidate their distinct and collaborative roles in tumorigenesis.
- To identify potential diagnostic and prognostic biomarkers and therapeutic targets.
Main Methods:
- Review of existing literature on MDM2, MDMX, and p53 interactions in cancer.
- Analysis of cancer genomics data to identify dysregulation patterns.
- Functional studies investigating oncogenic mechanisms.
Main Results:
- MDM2 and MDMX are frequently dysregulated in various human cancers.
- Both proteins contribute to oncogenesis through p53 inhibition and potentially other pathways.
- Their combined or individual actions are critical in tumor development.
Conclusions:
- Understanding MDM2 and MDMX functions is crucial for cancer diagnosis and prognosis.
- Targeting MDM2, MDMX, or their regulators presents a promising therapeutic avenue for cancer treatment.
Related Concept Videos
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Epigenetic Regulation

